Ophthalmology News

OCU410, a single-dose modifier gene therapy, demonstrated positive preliminary outcomes for the treatment of geographic atrophy in a phase 1/2 clinical trial, according to a press release from Ocugen.

NEW YORK — In this Healio Video Perspective from OSN New York, William B. Trattler, MD, of the Center for Excellence in Eye Care in Miami, discusses how the EVO ICL may be beneficial for patients with keratoconus and myopia.

CHICAGO — In this video, Karl G. Csaky, MD, PhD, discusses highlights from the AAO annual meeting.

The FDA granted rare pediatric disease and fast track designations to gildeuretinol, an investigational oral therapy for the treatment of Stargardt disease, according to a press release from Alkeus Pharmaceuticals.

The European Commission has approved Opuviz 40 mg/mL solution, a biosimilar referencing Eylea, according to a press release from Samsung Bioepis and Biogen.

Eyenovia’s phase 3 CHAPERONE study evaluating low-dose atropine delivered via the company’s Optejet dispenser is not meeting its primary endpoint of a less than 0.50 D progression in visual acuity over 3 years, according to a press release.

CHICAGO — In this video, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses study results presented at the AAO meeting on ONL1204 from ONL Therapeutics.

Adverum Biotechnologies reported positive 52-week data from the phase 2 LUNA trial as well as long-term follow-up results from the OPTIC trial of Ixo-vec in patients with wet age-related macular degeneration.

NEW YORK — In this Healio Video Perspective from OSN New York, John A. Hovanesian, MD, FACS, of Harvard Eye Associates discusses three tools to improve cataract surgery planning.

Evaluations of diabetic retinopathy severity appeared comparable with ultra-widefield and 7-field imaging, suggesting ultra-widefield imaging can be used in future longitudinal studies without bias, according to a cross-sectional study.